Biologics

March 28th 2024

Research underscores concerns that cost-sharing policies may contribute healthcare disparities.

March 21st 2024

But Amgen and Sandoz are in a patent fight over the launching of Sandoz's biosimilars to the bone-building drugs.

March 20th 2024

Zymfentra, with a price of $6,181.08 for two shots over four weeks, is approved as maintenance therapy for adults with ulcerative colitis and Crohn’s disease.

March 19th 2024

The market for Humira biosimilars may be shrinking as AbbVie works to boost prescriptions for its next-generation anti-inflammatories, Skyrizi (risankizumab) and Rinvoq (upadacitinib).